# Sonoma Pharmaceuticals Inc. (SNOA)

Source: https://www.quantisnow.com/company/SNOA
Generated: 2026-11-19T02:57:11.665Z

- Ticker: SNOA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- IPO year: 2007
- SEC CIK: 0001367083
- Website: sonomapharma.com

## About

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

## Latest SNOA news and filings

- 2026-11-13 21:31 UTC [SEC Form S-3] [SEC Form S-3 filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-sonoma-pharmaceuticals-inc-6790986)
- 2026-11-10 21:10 UTC [Market Insight] [Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-reports-second-fiscal-quarter-2027-financial-results-delivering-6784056)
- 2026-11-10 21:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-sonoma-pharmaceuticals-inc-6783770)
- 2026-10-06 20:34 UTC [Amendment: SEC Form 8-A12B/A filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-8-a12ba-filed-by-sonoma-pharmaceuticals-inc-6739159)
- 2026-10-06 20:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-sonoma-pharmaceuticals-inc-6739125)
- 2026-08-19 21:27 UTC [SEC Form 8-K] [Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-inc-filed-sec-form-8-k-submission-of-matters-6688862)
- 2026-08-06 13:00 UTC [Market Insight] [Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-delivers-141-us-revenue-growth-in-fy-q1-6667767)
- 2026-08-06 12:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-sonoma-pharmaceuticals-inc-6667672)
- 2026-07-28 20:50 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-sonoma-pharmaceuticals-inc-6651993)
- 2026-07-22 23:09 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-sonoma-pharmaceuticals-inc-6645950)
- 2026-07-10 00:47 UTC [SEC Form 4] [SEC Form 4 filed by Director Weigerstorfer Philippe](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-weigerstorfer-philippe-6633463)
- 2026-07-10 00:47 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Trombly Amy Moss](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-trombly-amy-6633462)
- 2026-07-10 00:47 UTC [SEC Form 4] [SEC Form 4 filed by Director Mclaughlin John](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mclaughlin-john-6633461)
- 2026-07-10 00:47 UTC [SEC Form 4] [SEC Form 4 filed by Director Jacoby Vanessa](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-jacoby-vanessa-6633460)
- 2026-07-10 00:46 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Dvonch Jerome J](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-dvonch-jerome-6633458)
- 2026-07-10 00:46 UTC [SEC Form 4] [SEC Form 4 filed by Controller Dal Poggetto John](https://www.quantisnow.com/insight/sec-form-4-filed-by-controller-dal-poggetto-john-6633457)
- 2026-07-09 20:30 UTC [SEC Form S-8] [SEC Form S-8 filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-sonoma-pharmaceuticals-inc-6633187)
- 2026-06-30 13:00 UTC [Market Insight] [Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-receives-fda-510k-clearance-expanding-indications-and-packaging-6620228)
- 2026-06-24 21:17 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-sonoma-pharmaceuticals-inc-6614584)
- 2026-06-18 20:33 UTC [SEC Form 8-K] [Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-inc-filed-sec-form-8-k-other-events-financial-6609083)
- 2026-06-18 20:30 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-sonoma-pharmaceuticals-inc-6608998)
- 2026-06-16 20:15 UTC [Market Insight] [Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-reports-fiscal-year-and-fourth-quarter-2026-financial-6604778)
- 2026-06-16 20:02 UTC [SEC Form 10-K] [SEC Form 10-K filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-sonoma-pharmaceuticals-inc-6604583)
- 2026-05-05 20:55 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-sonoma-pharmaceuticals-inc-6532958)
- 2026-04-30 21:00 UTC [SEC Form 8-K] [Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6525283)
- 2026-04-27 10:00 UTC [SEC Form 424B4 filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b4-filed-by-sonoma-pharmaceuticals-inc-6515277)
- 2026-04-25 01:21 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-sonoma-pharmaceuticals-inc-6515263)
- 2026-04-24 13:21 UTC [Market Insight] [Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-announces-pricing-of-4-million-public-offering-6513864)
- 2026-04-24 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-sonoma-pharmaceuticals-inc-6513435)
- 2026-04-23 00:07 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-sonoma-pharmaceuticals-inc-6511254)
- 2026-04-17 21:23 UTC [SEC Form S-1] [SEC Form S-1 filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-sonoma-pharmaceuticals-inc-6505375)
- 2026-04-09 12:30 UTC [SEC Form 8-K] [Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6494055)
- 2026-03-24 12:30 UTC [Market Insight] [Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-announces-us-retail-launch-of-advanced-burn-relief-6466286)
- 2026-03-18 12:30 UTC [Market Insight] [Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-announces-launch-of-new-dermatology-product-line-under-6455433)
- 2026-02-10 21:10 UTC [Market Insight] [Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-reports-third-fiscal-quarter-2026-financial-results-6384144)
- 2026-02-10 21:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-sonoma-pharmaceuticals-inc-6383928)
- 2026-02-09 22:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Jacoby Vanessa](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-jacoby-vanessa-6382258)
- 2026-01-28 21:15 UTC [Market Insight] [Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-welcomes-new-member-of-its-board-of-directors-6364087)
- 2026-01-28 21:01 UTC [SEC Form 8-K] [Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-financial-6363888)
- 2026-01-12 13:30 UTC [SEC Form 8-K] [Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/sonoma-pharmaceuticals-inc-filed-sec-form-8-k-other-events-financial-6345808)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SNOA
- Earnings history: https://www.quantisnow.com/earnings/SNOA
- Dividend history: https://www.quantisnow.com/dividends/SNOA
- Insider transactions: https://www.quantisnow.com/insiders/SNOA
- Options chain: https://www.quantisnow.com/options/SNOA
- SEC 8-K filings only: https://www.quantisnow.com/company/SNOA/8-k
- RSS and alerts for SNOA: https://www.quantisnow.com/docs/rss-feeds.md
